Table 1.

Antiviral Profiles of DNJ Derivatives 1–3 & 6–7 against BVDV Infection in MDBK Cells^a

Compounds (R =)	EC50 (μM)	CC50 (μM)	SI
6	1.1	350	318
7	6.2	> 500	> 81
1a	3.0	450	150
1b	7.5	> 500	> 67
1c	0.6	> 500	> 833
2a	0.4	480	1200
2b	0.3	> 500	> 1667
2c	1.5	450	300
2d	0.4	> 500	> 1250
2e	0.5	150	300
2f	1.8	190	106
2g	1.2	> 500	> 417
2h	3.5	> 500	> 143
2i	0.8	250	312
2j	0.5	200	400
2k	0.3	> 500	> 1667
2l	1.4	> 500	> 357
3a	0.9	> 500	> 556
3b	0.4	> 500	> 1250
3c	0.6	> 500	> 833
3d	0.4	> 500	> 1250
3e	0.7	90	129
3f	0.6	62	103
3g	0.6	85	142
3h	1.5	320	213
3i	2.8	> 500	> 179
3j	0.5	> 500	> 1000
3k	0.3	> 500	> 1667
3l	0.5	> 500	> 1000
3m	5.0	> 500	> 100
3n	1.0	> 500	> 500
3o	1.0	> 500	> 500
3p	1.5	> 500	> 333
3q	1.1	> 500	> 455
3r	1.3	> 500	> 385
3s	1.0	> 500	> 500
3t	1.0	> 500	> 500
3u	2.5	> 500	> 200
3v	1.5	> 500	> 333

^aEC₅₀: 50% effective concentration, measured by virus yield reduction assay; CC₅₀: 50% cytotoxic concentration, measured by MTT assay; SI: selective index, SI = CC₅₀/EC₅₀.